Glucotrack, Inc. (GCTK) · Aug 5, 2026 · Company update

Glucotrack raises $5.5 million, but at highly dilutive, creditor-friendly terms

Glucotrack raises $5.5 million, but at highly dilutive, creditor-friendly terms

The filing adds meaningful liquidity beyond the recently announced bridge. The prior July 14 bridge raised approximately $4.45 million; this follow-on brings another $5.5 million, taking gross financing announced across the two transactions to roughly $9.95 million. No published consensus expectation is provided, so the relevant baseline is the company’s obvious need for additional capital after the initial bridge. *(Follow-On Financing; Exhibit 99.1)*

Financing componentTermsInvestor exposure
Follow-on bridge notes$3.50 million principal; $4.49 million face value; 22% original issue discount; 8% interest; maturity nine months from July 14, 2026Senior secured debt with first-priority claims on company assets, excluding specified operating assets *(Follow-On Bridge Notes)*
Interim PIPE$2.00 million at $0.75 per unit2.67 million pre-funded warrant shares at a $0.0001 exercise price *(Interim PIPE)*
Common warrants—Warrants for 2.67 million shares at $1.50 per share, exercisable for five years *(Interim PIPE)*
Registration rights—Resale registration due to be filed within 30 days and targeted for effectiveness within 60 days, or 90 days after full SEC review *(Registration Rights Agreement, Sections 2.1–2.4)*

The cash runway benefit is real, but the financing is expensive. The equity portion is priced at $0.75 and comes with a warrant for every share-equivalent purchased, while the debt carries a 22% discount from principal to face value and is secured ahead of common shareholders. That structure suggests investors demanded substantial protection rather than simply expressing unqualified confidence. *(Exhibit 99.1; Follow-On Bridge Notes)*

The dilution overhang is larger than the headline $2 million equity raise. The PIPE creates exposure to approximately 5.33 million shares through the pre-funded warrants and common warrants, before considering any shares issued if the $3.5 million bridge notes convert. Conversion is blocked until stockholder approval and can occur at the lower of the Nasdaq minimum price or 80% of a recent VWAP, subject to a low floor; the bridge warrants also require approval and have an exercise price formula tied to the company’s share count. *(Follow-On Bridge Notes; Follow-On Bridge Warrants)*

Net: this solves an immediate funding problem, not the capital-structure problem. Compared with the standing expectation that Glucotrack would need more money after the July bridge, raising another $5.5 million is incrementally helpful. But the secured debt, below-market conversion mechanics, warrant package, stockholder-approval dependency, and future resale registration leave common shareholders facing a substantial dilution and overhang risk. The filing therefore reads as a necessary financing win with unfavorable terms, rather than a clean positive surprise.

Original filing on SEC EDGAR

More Glucotrack, Inc. news

Glucotrack raises $5.5 million, but at highly dilutive, creditor-friendly terms | GCTK Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.